Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a report published on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Shares of NASDAQ AEZS opened at $2.14 on Tuesday. The stock has a market capitalization of $10.40 million, a price-to-earnings ratio of -0.63 and a beta of 1.57. The firm’s 50 day simple moving average is $1.99 and its 200-day simple moving average is $1.90. Aeterna Zentaris has a 12 month low of $1.36 and a 12 month high of $3.30.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.19). Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%. The firm had revenue of $0.12 million for the quarter.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.